

Supplementary Table 3. Multivariate logistic regression analysis with clinical factors to social disadvantages

Clinical factor	Odds ratio (95%CI), p-value		
	Unemployment or unwilling transfer (213/680 cases)	Decrease in income (244/680 cases)	Reduced social positivity (449/917 cases)
Age, yrs	6.82 (0.73-64.07), 0.093	0.68 (0.11-4.26), 0.68	0.23 (0.03-1.68), 0.15
Female (%)	0.87 (0.26-2.86), 0.82	0.49 (0.15-1.54), 0.22	1.91 (0.57-6.36), 0.29
Time since onset, yrs	0.14 (0.01-1.36), 0.090	1.40 (0.22-8.98), 0.72	4.48 (0.60-33.72), 0.15
Age at onset, yrs	0.15 (0.02-1.39), 0.094	1.49 (0.23-9.50), 0.67	4.50 (0.60-33.61), 0.14
Thymectomy, %	16.98 (1.02-282.51), 0.048	9.79 (1.10-86.92), 0.041	0.91 (0.11-7.30), 0.93
Thymoma, %	0.62 (0.15-2.52), 0.51	0.83 (0.22-3.22), 0.79	0.33 (0.08-1.43), 0.14
AChR-Ab-positivity, %	0.28 (0.04-1.79), 0.18	0.27 (0.05-1.42), 0.12	1.26 (0.24-6.60), 0.78
MuSK-Ab-positivity, %	13.13 (0.06-3071.64), 0.35	0.66 (0.02-24.06), 0.82	0.10 (0.00-3.69), 0.21
MGFA classification (Worst)	1.15 (0.62-2.14), 0.65	0.90 (0.51-1.61), 0.73	2.26 (1.16-4.41), 0.017
Bulbar symptoms, % (Worst)	0.88 (0.17-4.50), 0.88	1.08 (0.22-5.18), 0.92	0.38 (0.08-1.87), 0.23
Current MGC	1.15 (1.00-1.34), 0.057	1.16 (0.99-1.35), 0.063	1.17 (0.98-1.39), 0.08
Peak dose of PSL, mg/day	1.01 (0.97-1.05), 0.63	1.02 (0.99-1.06), 0.22	0.99 (0.95-1.02), 0.44
Duration of PSL \geq 20 mg/day, yrs	1.19 (0.80-1.75), 0.39	1.30 (0.86-1.94), 0.21	0.73 (0.49-1.10), 0.14
Current dose of PSL, mg/day	1.17 (0.99-1.39), 0.062	1.04 (0.92-1.19), 0.53	1.03 (0.91-1.17), 0.64
MM or better with 5 mg at 1 year into treatment, %	0.65 (0.11-3.90), 0.64	1.03 (0.20-5.34), 0.98	0.66 (0.13-3.46), 0.63
MM or better with 5 mg at 2 years into treatment, %	1.49 (0.28-7.98), 0.64	3.72 (0.73-19.02), 0.11	3.17 (0.50-19.92), 0.22
MM or better with 5 mg at 4 years into treatment, %	2.05 (0.37-11.22), 0.41	0.55 (0.12-2.65), 0.46	0.16 (0.03-0.98), 0.048
MM or better with 5 mg at present, %	1.29 (0.28-6.00), 0.74	1.72 (0.39-7.52), 0.47	0.73 (0.18-2.93), 0.66

Significant correlations are indicated bold font. AChR-Ab, antiacetylcholine receptor antibody; CI, confidence interval; MGC, Myasthenia Gravis Composite; MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; MG-QOL15, 15-item MG-specific quality of life scale; MG-QOL15-J, Japanese version of the MG-QOL15; MM, minimal manifestations; MuSK-Ab, muscle-specific kinase antibody; PSL, prednisolone; QMG, MGFA quantitative MG score.